Press coverage about Novartis (NYSE:NVS) has trended negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than 6,000 news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Novartis earned a coverage optimism score of -2.83 on their scale. InfoTrie also gave media stories about the company an news buzz score of 0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news headlines that may have impacted Novartis’ score:
- Novartis Settles US Bribery Charges – CFO Magazine (cfo.com)
- Novartis and Alcon to Pay $345M in Settlements Over Bribery Accusations – InvisionMag (invisionmag.com)
- Novartis, Units Admit Violating Bribery Law Bashed by Trump – Yahoo Canada Finance (ca.finance.yahoo.com)
- Novartis pulls dry eye drug Xiidra’s bid for approval in Europe – KFGO News (kfgo.com)
- Novartis to pay ~$113M to settle SEC charges of FCPA violations (seekingalpha.com)
Shares of NVS stock traded down $2.50 during trading on Friday, hitting $87.10. 1,876,877 shares of the company were exchanged, compared to its average volume of 1,934,168. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.53 and a current ratio of 0.74. The firm has a market capitalization of $205.07 billion, a price-to-earnings ratio of 16.62, a P/E/G ratio of 1.97 and a beta of 0.51. The business’s 50-day simple moving average is $86.35 and its 200 day simple moving average is $88.72. Novartis has a twelve month low of $69.18 and a twelve month high of $99.84.
Several research analysts have commented on NVS shares. UBS Group reiterated a “neutral” rating on shares of Novartis in a report on Monday, May 11th. ValuEngine cut shares of Novartis from a “hold” rating to a “sell” rating in a report on Friday, June 5th. Barclays reiterated an “underweight” rating on shares of Novartis in a report on Wednesday, April 29th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Novartis in a report on Wednesday, April 29th. Finally, Goldman Sachs Group reiterated a “buy” rating and issued a $116.00 target price on shares of Novartis in a report on Friday, April 3rd. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $105.25.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Recommended Story: How to Profit and Limit Losses With Stop Orders
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.